References
- Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol 2001; 115: 272–278
- Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53–59
- Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356–1363
- Isasi C R, Lu P, Blaufox M D. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104: 1066–1074
- Kazama T, Faria S C, Varavithya V, Phongkitkarun S, Ito H, Macapinlac H A. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005; 25: 191–207
- Blum R, Seymour J F, Hicks R J. Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma 2002; 43: 2155–2157
- Buchler T, Cervinek L, Belohlavek O, Kantorova I, Mechl M, Nebesky T, Vorlicek J, et al. Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer 2005; 44: 286–288
- Calming U, Bemstrand C, Mosskin M, Elander S S, Ingvar M, Henter J I. Brain 18-FDG PET scan in central nervous system langerhans cell histiocytosis. J Pediatr 2002; 141: 435–440
- Steiner M, Prayer D, Asenbaum S, Prosch H, Minkov M, Unger E, et al. Modern imaging methods for the assessment of Langerhans' cell histiocytosis-associated neurodegenerative syndrome: case report. J Child Neurol 2005; 20: 253–257
- Binkovitz L A, Olshefski R S, Adler B H. Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol 2003; 33: 598–602
- Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219: 774–777
- Pereira Neto C C, Roman C, Johnson M, Jagasia M, Martin W H, Delbeke D. Positron emission tomography/computed tomography of a rare xanthogranulomatous process: Erdheim-Chester disease. Mol Imaging Biol 2004; 6: 63–67
- Scanagatta P, Bonadiman C, Falezza G, Terzi A, Magnanelli G, Benato C, et al. [Mediastinoscopy for diagnosis of diseases of the chest and staging of lung cancer: our experience in 253 cases]. Chir Ital 2005; 57: 177–182
- Porte H, Roumilhac D, Eraldi L, Cordonnier C, Puech P, Wurtz A. The role of mediastinoscopy in the diagnosis of mediastinal lymphadenopathy. Eur J Cardiothorac Surg 1998; 13: 196–199
- Lemaire A, Nikolic I, Petersen T, Haney J C, Toloza E M, Harpole D H, Jr, et al. Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. Ann Thorac Surg 2006; 82: 1185–1189, discussion 1189 – 1190